** Shares of drug developer Sagimet Biosciences SGMT.O rise 52% to $5.53 premarket
** SGMT says its oral acne drug, denifanstat, met the main goals in a late-stage trial conducted by its Chinese partner Ascletis 1672.HK
** Denifanstat showed 33.2% treatment success rate versus 14.6% for placebo
** Denifanstat works by inhibiting the production of sebum, a key contributor to acne, through a novel mechanism of action, co says
** The drug reduced total acne lesions by 57.4% compared to 35.4% with placebo
** Ascletis plans to submit denifanstat for approval to Chinese regulators
** As of last close, stock down 19.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.